Company intelligence / Profile preview

Early-stage Neurotechnology

London/Oxford, United Kingdomnewswire.ca ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

Mendea develops non-invasive wearable brain stimulation devices using low-intensity focused ultrasound. Their goal is to provide safe and customizable neuromodulation solutions for both clinical therapy and enhancement in healthy users. The team includes experts from Imperial College London and Oxford University. No published clinical results yet; still pre-commercialization.

Therapeutic areas: NeurologyOther
Modalities: DeviceNon-invasive neuromodulation technology (specifically low-intensity focused ultrasound)
Industry: Therapeutic Medical Devices

Partnerships

Academic partnerships with Imperial College London and Oxford University researchers.

Beyond the preview

Go deeper on Early-stage Neurotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Early-stage Neurotechnology.

Explore the full profile